{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:11:03Z","timestamp":1791267063488,"version":"4.1.0"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH196"],"award-info":[{"award-number":["ZR2023QH196"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH334"],"award-info":[{"award-number":["ZR2024MH334"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303905"],"award-info":[{"award-number":["82303905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303911"],"award-info":[{"award-number":["82303911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473405"],"award-info":[{"award-number":["82473405"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M721929"],"award-info":[{"award-number":["2022M721929"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although immunotherapy has revolutionized cancer treatment, its efficacy in castration-resistant prostate cancer (CRPC) remains limited, largely due to an immunologically \u201ccold\u201d tumor microenvironment with scarce T-cell infiltration. Unraveling the molecular mechanisms underlying immune evasion and developing novel strategies to activate innate antitumor immunity are therefore critical to overcoming immunotherapy resistance in CRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using bioinformatic approaches, we analyzed the protein kinase membrane-associated tyrosine\/threonine 1 (PKMYT1) expression and its correlation with immune cell infiltration and response to immune checkpoint blockade (ICB) in public databases. PKMYT1 protein expression was further evaluated via immunohistochemistry in a clinical cohort of prostate cancer (PCa) specimens. Mechanistic investigations were conducted in PCa cell lines and mouse models. The immunological impact of PKMYT1 inhibition was delineated using single-cell RNA sequencing, and the therapeutic efficacy of RP-6306, either as monotherapy or in combination with programmed death-ligand 1 (PD-L1) blockade, was evaluated in syngeneic mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PKMYT1 expression was significantly overexpressed in CRPC compared with primary PCa. High PKMYT1 expression correlated with a suppressed antitumor immunity and poor clinical response to ICB. Mechanistically, PKMYT1 inhibition activated the cyclic guanosine monophosphate-adenosine monophosphate adenosine synthase (cGAS)-stimulator of interferon genes (STING) pathway, potentiated both type I and II interferon signaling, and upregulated chemokines, including CCL5 and CXCL10. The selective PKMYT1 inhibitor, RP-6306, enhanced the efficacy of ICB in the presence of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Treatment with a PKMYT1 inhibitor alone or in combination with PD-L1 blockade significantly increased the infiltration of activated CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and induced significant tumor suppression in vivo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PKMYT1 is a pivotal dual regulator of tumor progression and immune evasion in CRPC. Our findings provide a compelling preclinical rationale for targeting PKMYT1 as a novel strategy to reprogram the tumor immune microenvironment and overcome resistance to immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013247","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:35:22Z","timestamp":1769772922000},"page":"e013247","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05147350","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05147272","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04855656","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05601440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04855656","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-2410","authenticated-orcid":false,"given":"Lin","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Pathology & Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"},{"name":"School of Life Sciences and Health, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1817-3770","authenticated-orcid":false,"given":"Baozhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6246-3395","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0133-6860","authenticated-orcid":false,"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5477-8148","authenticated-orcid":false,"given":"Long","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7133-0759","authenticated-orcid":false,"given":"Jingying","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-754X","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0389-9949","authenticated-orcid":false,"given":"Baokai","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9304-0244","authenticated-orcid":false,"given":"Feifei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8906-8216","authenticated-orcid":false,"given":"Wenyao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-1580","authenticated-orcid":false,"given":"Xinpei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6655-9263","authenticated-orcid":false,"given":"Tingting","family":"Feng","sequence":"additional","affiliation":[{"name":"Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9389-5399","authenticated-orcid":false,"given":"Ru","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-3029","authenticated-orcid":false,"given":"Xiaorong","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-4101","authenticated-orcid":false,"given":"Weiwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology & Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-6732","authenticated-orcid":false,"given":"Jing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-1398","authenticated-orcid":false,"given":"Bo","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026013003351654000_14.1.e013247.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026013003351654000_14.1.e013247.2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41419-022-05392-6","article-title":"SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXR\u03b1\/FOXM1 pathway independently of REV-ERBs","volume":"13","author":"Xu","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026013003351654000_14.1.e013247.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30496-X"},{"key":"2026013003351654000_14.1.e013247.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01638"},{"key":"2026013003351654000_14.1.e013247.5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081778","article-title":"The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer","volume":"10","author":"Xu","year":"2022","journal-title":"Biomedicines"},{"key":"2026013003351654000_14.1.e013247.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.04.029"},{"key":"2026013003351654000_14.1.e013247.7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","article-title":"EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer","volume":"2","author":"Morel","year":"2021","journal-title":"Nat Cancer"},{"key":"2026013003351654000_14.1.e013247.8","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature New Biol"},{"key":"2026013003351654000_14.1.e013247.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2020.07.008"},{"key":"2026013003351654000_14.1.e013247.10","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22122045","article-title":"Regulation of G2\/M Transition by Inhibition of WEE1 and PKMYT1 Kinases","volume":"22","author":"Schmidt","year":"2017","journal-title":"Molecules"},{"key":"2026013003351654000_14.1.e013247.11","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000826"},{"key":"2026013003351654000_14.1.e013247.12","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.21037\/tlcr-21-973","article-title":"The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies","volume":"10","author":"Shao","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"2026013003351654000_14.1.e013247.13","first-page":"4210","article-title":"Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway","volume":"23","author":"Sun","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026013003351654000_14.1.e013247.14","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12741","article-title":"Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif"},{"key":"2026013003351654000_14.1.e013247.15","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S255746"},{"key":"2026013003351654000_14.1.e013247.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144608"},{"key":"2026013003351654000_14.1.e013247.17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature New Biol"},{"key":"2026013003351654000_14.1.e013247.18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00552"},{"key":"2026013003351654000_14.1.e013247.19","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/0008-5472.CAN-23-4130","article-title":"Low\u2013Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"key":"2026013003351654000_14.1.e013247.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2019.05.007"},{"key":"2026013003351654000_14.1.e013247.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1965"},{"key":"2026013003351654000_14.1.e013247.22","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1038\/s41388-022-02332-8","article-title":"RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway","volume":"41","author":"Sun","year":"2022","journal-title":"Oncogene"},{"key":"2026013003351654000_14.1.e013247.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003"},{"key":"2026013003351654000_14.1.e013247.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902651116"},{"key":"2026013003351654000_14.1.e013247.25","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4053"},{"key":"2026013003351654000_14.1.e013247.26","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"2026013003351654000_14.1.e013247.27","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.828657","article-title":"DNA Damage and Activation of cGAS\/STING Pathway Induce Tumor Microenvironment Remodeling","volume":"9","author":"Shen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026013003351654000_14.1.e013247.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1010"},{"key":"2026013003351654000_14.1.e013247.29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41590-021-00896-3","article-title":"The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFN-\u03b2 pathway","volume":"22","author":"Takahashi","year":"2021","journal-title":"Nat Immunol"},{"key":"2026013003351654000_14.1.e013247.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16933-6"},{"key":"2026013003351654000_14.1.e013247.31","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.7150\/thno.100555","article-title":"Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management","volume":"14","author":"Hansen","year":"2024","journal-title":"Theranostics"},{"key":"2026013003351654000_14.1.e013247.32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.eururo.2024.04.026","article-title":"The Role of Microsatellite Instability\/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer","volume":"86","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur Urol"},{"key":"2026013003351654000_14.1.e013247.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-02973-1","article-title":"Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration","volume":"11","author":"Long","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026013003351654000_14.1.e013247.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01600-6"},{"key":"2026013003351654000_14.1.e013247.35","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature New Biol"},{"key":"2026013003351654000_14.1.e013247.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2371"},{"key":"2026013003351654000_14.1.e013247.37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026013003351654000_14.1.e013247.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.04.034"},{"key":"2026013003351654000_14.1.e013247.39","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01730-1","article-title":"Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma","volume":"18","author":"Kim","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026013003351654000_14.1.e013247.40","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02250-7","article-title":"PKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026013003351654000_14.1.e013247.41","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad029","article-title":"Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma","volume":"5","author":"Benada","year":"2023","journal-title":"NAR Cancer"},{"key":"2026013003351654000_14.1.e013247.42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature New Biol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:35:26Z","timestamp":1769772926000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,30]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-013247"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013247","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}